<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-140931</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Therapeutic update in hepatitis C</dc:title>
<dc:description xml:lang="en">Hepatitis C virus infection is a major health burden affecting 130-170 million people worldwide. Approximately 10-30% of those with chronic hepatitis C will progress to cirrhosis over 20-30 years. The development of new direct-acting antivirals has changed the management of the disease, allowing efficacious Interferon-free therapies superior to prior treatment regimens with minimal side effects, even in some subgroups previously thought to be difficult to cure such as cirrhotic patients (AU)</dc:description>
<dc:creator>Díaz-Rubio, Manuel</dc:creator>
<dc:creator>Cuenca, Francisca</dc:creator>
<dc:creator>Izquierdo, Sonia</dc:creator>
<dc:creator>Devesa, María José</dc:creator>
<dc:creator>Sánchez-Pobre, Pilar</dc:creator>
<dc:creator>Rey, Enrique</dc:creator>
<dc:creator>Ladero, José María</dc:creator>
<dc:creator>López-Alonso, Gustavo</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La infección por el virus de hepatitis C es un problema de salud que afecta a 130-170 millones de personas en todo el mundo. Aproximadamente un 10-30% de pacientes con hepatitis crónica C progresarán a cirrosis en 20-30 años. El desarrollo de nuevos agentes antivirales de acción directa ha cambiado el manejo de la enfermedad, permitiendo el tratamiento libre de Interferón con eficacia superior a los regímenes terapéuticos previos y mínimos efectos adversos, incluso en algunos subgrupos previamente considerados difíciles de curar como los pacientes cirróticos (AU)</dc:description>
<dc:source>Rev Esp Quimioter;28(supl.1): 48-51, sept. 2015.</dc:source>
<dc:identifier>ibc-140931</dc:identifier>
<dc:title xml:lang="es">Actualización terapéutica en la hepatitis C</dc:title>
<dc:subject>^d30351^s22054</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d1002^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d30351^s22080</dc:subject>
<dc:subject>^d8276^s22012</dc:subject>
<dc:subject>^d29469^s22073</dc:subject>
<dc:subject>^d3162^s22045</dc:subject>
<dc:subject>^d24873^s22001</dc:subject>
<dc:subject>^d30351^s22034</dc:subject>
<dc:subject>^d30351^s22067</dc:subject>
<dc:subject>^d30351^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>201509</dc:date>
</metadata>
</record>
</ibecs-document>
